The study includes protein-ligand and peptide-protein docking of twenty anti-inflammatory peptides counter to IFN-γ, IL-3, and TNF-α receptor proteins as targets for the treatment of SLE. This evidence concerns the gene IFNG and systemic lupus erythematosus.